Dana-Farber Cancer Institute scientists create a peptide “cocktail” that elicits immune response to multiple myeloma:
NCI Cancer Center News
Scientists at Dana-Farber Cancer Institute have created a “cocktail” of immune-stimulating peptides they believe could provoke the body’s defenses to attack multiple myeloma in its early “smoldering” phase and slow or prevent the blood cancer. Based on laboratory results presented at the annual meeting of the American Society of Hematology, the researchers say the immunotherapy approach merits testing in human clinical trials.
Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.